Skip to main content

Table 7 mRNA expression of the 49 dysregulated genes in aneuploid tumors relative to diploid tumors

From: Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

Genes

Diploid tumors

(n = 24)

Aneuploid tumor

(n = 23)

pa

ROC-AUCb

PLK1

1,67 (0,69-7,46) c

8,65 (2,26-35,59)

0,0000005

0,929

AURKA

4,41 (1,46-15,80)

12,92 (3,88-34,22)

0,0000006

0,924

CCNB1

2,23 (0,34-19,16)

5,56 (2,67-18,97)

0,000002

0,901

BUB1

2,96 (0,74-10,74)

6,75 (1,88-25,63)

0,00008

0,837

CDC20

1,76 (0,39-7,95)

4,70 (1,39-22,65)

0,0001

0,824

TACC3

3,81 (1,01-12,27)

8,47 (2,62-29,89)

0,0002

0,814

CDC2

4,77 (1,19-23,21)

14,39 (3,51-56,17)

0,0005

0,797

ZWINT

3,74 (1,08-14,24)

5,97 (2,61-20,70)

0,0005

0,795

BUB3

1,73 (0,74-3,63)

2,89 (1,08-10,17)

0,0007

0,789

NDC80

4,30 (1,05-23,45)

10,00 (2,96-126,38)

0,0009

0,784

TPX2

9,63 (1,65-35,79)

22,11 (5,45-117,11)

0,0009

0,783

RAD21

1,61 (0,65-5,69)

3,03 (0,78-10,73)

0,001

0,770

MAD2L2

1,20 (0,39-3,66)

1,91 (0,61-7,41)

0,002

0,767

CDC23

1,27 (0,92-2,89)

1,96 (0,95-3,96)

0,002

0,765

PPP1R2

1,94 (0,83-3,46)

2,64 (1,03-4,91)

0,004

0,733

CENPE

7,58 (0,08-39,17)

17,11 (2,88-61,89)

0,007

0,729

PTTG1

2,60 (0,01-12,91)

4,03 (2,34-9,95)

0,007

0,729

BIRC5

9,76 (1,47-43,46)

23,21 (2,32-150,30)

0,007

0,728

AURKB

3,83 (0,61-20,14)

6,62 (1,02-64,52)

0,008

0,726

CCNB2

7,74 (2,00-68,51)

17,86 (3,53-55,08)

0,01

0,714

KNTC1

1,02 (0,44-3,63)

1,75 (0,50-3,70)

0,01

0,710

TTK

4,20 (0,61-16,04)

8,05 (1,72-44,27)

0,02

0,701

CCNA2

7,62 (2,45-32,82)

13,61 (2,20-35,30)

0,02

0,692

ESPL1

2,09 (0,44-9,64)

4,59 (0,68-10,11)

0,04

0,674

CDKN1A

1,50 (0,49-3,87)

2,08 (0,76-10,29)

NS

0,657

MAD2L1

1,92 (0,80-8,58)

2,34 (1,08-5,18)

NS

0,647

SMC1L2

0,19 (0,00-2,15)

0,70 (0,04-10,43)

NS

0,642

NEK2

18,34 (2,46-109,01)

29,31 (4,97-137,03)

NS

0,638

FBXW7

0,47 (0,16-1,30)

0,61 (0,30-1,18)

NS

0,631

BUB1B

6,32 (1,35-63,78)

11,35 (3,25-27,28)

NS

0,626

UBD

3,47 (0,15-41,74)

4,94 (0,44-106,40)

NS

0,605

CCNB3

5,90 (0,75-27,35)

6,77 (1,29-61,53)

NS

0,601

CDC27

1,69 (0,74-2,46)

1,90 (0,65-5,77)

NS

0,599

ANAPC4

0,86 (0,31-1,84)

0,90 (0,38-1,90)

NS

0,592

MRE11A

0,72 (0,25-1,46)

0,89 (0,21-2,31)

NS

0,592

ZWILCH

1,79 (0,76-4,98)

2,26 (0,98-3,50)

NS

0,589

BRCA2

1,37 (0,31-7,84)

2,06 (0,69-4,87)

NS

0,581

UBE2N

2,08 (1,53-3,42)

2,34 (1,58-3,42)

NS

0,574

RAN

1,88 (1,05-3,33)

2,09 (1,28-15,85)

NS

0,550

STAG1

0,56 (0,23-1,03)

0,58 (0,31-0,94)

NS

0,549

RAE1

2,03 (1,37-4,32)

2,14 (1,15-2,88)

NS

0,519

AURKC

0,77 (0,37-3,08)

0,75 (0,35-10,67)

NS

0,496

AURKAIP1

2,00 (0,77-3,55)

1,83 (1,05-3,93)

NS

0,466

PPP1CA

2,57 (1,23-9,80)

2,15 (1,26-11,11)

NS

0,440

TACC1

1,14 (0,26-2,93)

0,99 (0,23-2,81)

NS

0,430

RASSF1A

0,55 (0,10-2,13)

0,46 (0,16-1,35)

NS

0,413

ANAPC7

2,32 (1,33-4,41)

2,22 (1,39-3,46)

NS

0,399

PRCC

3,67 (1,94-6,62)

2,96 (1,62-6,35)

NS

0,388

UBE1C

1,70 (0,67-3,71)

1,41 (0,52-2,65)

NS

0,384

ANAPC2

1,05 (0,46-2,63)

0,95 (0,57-1,62)

NS

0,365

FZR1

0,75 (0,29-1,49)

0,56 (0,24-1,41)

0,001

0,225

HTERT

1,00 (0,51-4,11)

1,69 (0,33-28,84)

0,04

0,678

MKI67

1,00 (0,20-4,70)

2,20 (0,72-7,41)

0,0009

0,782

ESR1

1,00 (0,29-2,78)

0,89 (0,00-3,77)

NS

0,426

  1. aKruskal Wallis' H Test
  2. bROC (Receiver Operating Characteristics) - AUC (Area Under the Curve) analysis
  3. cMedian (range) gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 9 normal breast tissues mRNA levels was 1.
Back to article page

Molecular Cancer

ISSN: 1476-4598